JP2023547323A5 - - Google Patents

Info

Publication number
JP2023547323A5
JP2023547323A5 JP2023519662A JP2023519662A JP2023547323A5 JP 2023547323 A5 JP2023547323 A5 JP 2023547323A5 JP 2023519662 A JP2023519662 A JP 2023519662A JP 2023519662 A JP2023519662 A JP 2023519662A JP 2023547323 A5 JP2023547323 A5 JP 2023547323A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023519662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023547323A (ja
JP7767411B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/056018 external-priority patent/WO2022087243A1/en
Publication of JP2023547323A publication Critical patent/JP2023547323A/ja
Publication of JP2023547323A5 publication Critical patent/JP2023547323A5/ja
Application granted granted Critical
Publication of JP7767411B2 publication Critical patent/JP7767411B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023519662A 2020-10-22 2021-10-21 抗fgfr2抗体及びその使用方法 Active JP7767411B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063104377P 2020-10-22 2020-10-22
US63/104,377 2020-10-22
US202163220948P 2021-07-12 2021-07-12
US63/220,948 2021-07-12
US202163253858P 2021-10-08 2021-10-08
US63/253,858 2021-10-08
PCT/US2021/056018 WO2022087243A1 (en) 2020-10-22 2021-10-21 Anti-fgfr2 antibodies and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2023547323A JP2023547323A (ja) 2023-11-10
JP2023547323A5 true JP2023547323A5 (cg-RX-API-DMAC7.html) 2024-10-17
JP7767411B2 JP7767411B2 (ja) 2025-11-11

Family

ID=78806631

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519662A Active JP7767411B2 (ja) 2020-10-22 2021-10-21 抗fgfr2抗体及びその使用方法

Country Status (13)

Country Link
US (2) US11866502B2 (cg-RX-API-DMAC7.html)
EP (1) EP4232481A1 (cg-RX-API-DMAC7.html)
JP (1) JP7767411B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230095070A (cg-RX-API-DMAC7.html)
CN (1) CN116406379A (cg-RX-API-DMAC7.html)
AU (1) AU2021366691B2 (cg-RX-API-DMAC7.html)
CA (1) CA3190569A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001114A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023004110A2 (cg-RX-API-DMAC7.html)
IL (1) IL301702A (cg-RX-API-DMAC7.html)
MX (1) MX2023004434A (cg-RX-API-DMAC7.html)
NZ (1) NZ797493A (cg-RX-API-DMAC7.html)
WO (1) WO2022087243A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132658A2 (en) * 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
KR20250126131A (ko) * 2022-12-28 2025-08-22 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
CN118994393A (zh) * 2023-05-19 2024-11-22 广东东阳光药业股份有限公司 一种抗fgfr2抗体及其应用
EP4786494A1 (en) * 2023-09-28 2026-08-05 Nanjing Leads Biolabs Co., Ltd. Anti-fgfr2 antibody and multispecific binding molecule comprising same
TW202540177A (zh) * 2023-11-14 2025-10-16 大陸商蘇州創勝醫藥集團有限公司 抗-FGFR2b免疫偶聯物及其於治療癌症的用途
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
WO2025130905A1 (zh) 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体-药物缀合物及其应用
WO2025146131A1 (en) * 2024-01-05 2025-07-10 Beigene, Ltd. ANTI-FGFR2b ANTIBODIES, CONJUGATES AND METHODS OF USE
CN120424212A (zh) * 2024-01-26 2025-08-05 上海安领科生物医药有限公司 抗FGFR2b抗体及抗体药物偶联物
WO2025209434A1 (zh) * 2024-04-01 2025-10-09 思康睿奇(上海)药业有限公司 抗FGFR2b抗体药物偶联物及其应用
WO2025218662A1 (zh) * 2024-04-16 2025-10-23 杭州中美华东制药有限公司 抗成纤维细胞生长因子受体2b的抗体及其用途
CN121319178A (zh) * 2024-07-02 2026-01-13 安博泰克药业有限公司 特异性结合FGFR2b的抗体及其与药物的缀合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1231260B (it) 1988-11-16 1991-11-28 Sergio Bertini Curri Farmaco e metodo per aumentare volume e velocita' del flusso microcircolatorio capillare a livello cutaneo
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
CA2556752C (en) 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
US7985557B2 (en) 2007-05-23 2011-07-26 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
ES2560807T3 (es) 2008-07-21 2016-02-22 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
DK3290052T3 (da) 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
KR101000067B1 (ko) 2008-12-30 2010-12-10 엘지전자 주식회사 고효율 태양전지용 레이저 소성장치 및 고효율 태양전지 제조방법
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
DK2889624T3 (en) 2009-08-10 2018-12-10 Ucl Business Plc Reversible covalent bonding of functional molecules
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
DK2714685T3 (en) 2011-05-27 2017-01-09 Ambrx Inc FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6166728B2 (ja) 2011-10-14 2017-07-19 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
AU2012322934B2 (en) 2011-10-14 2016-09-08 Medimmune Limited Pyrrolobenzodiazepines
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
BR112014013526A8 (pt) 2011-12-05 2017-06-13 Igenica Biotherapeutics Inc conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
HRP20180268T4 (hr) 2012-10-23 2026-03-27 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
WO2014089193A1 (en) * 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
MX374785B (es) * 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
AU2014311361B2 (en) 2013-08-26 2018-11-29 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
CN105792844B (zh) * 2013-10-08 2021-03-02 第一三共株式会社 抗fgfr2抗体和另一药剂的组合
TWI871999B (zh) 2014-04-10 2025-02-01 日商第一三共股份有限公司 抗her3抗體-藥物結合物
CA2943299A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Bispecific her2 antibodies
CA2978340C (en) 2015-03-27 2024-05-28 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
MX390630B (es) 2016-01-25 2025-03-21 Regeneron Pharma Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
WO2018044540A1 (en) 2016-08-31 2018-03-08 Regeneron Pharmaceuticals, Inc. Compositions and methods for detecting protein trafficking
CA3042428A1 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
JP7685999B2 (ja) * 2019-12-24 2025-05-30 ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド 新規抗FGFR2b抗体
US11866502B2 (en) 2020-10-22 2024-01-09 Regeneron Pharmaceuticals, Inc. Anti-FGFR2 antibodies and methods of use thereof

Similar Documents

Publication Publication Date Title
JP7330996B2 (ja) Cd73を標的とする抗体および抗体-薬物複合体、その製造方法と使用
JP7402807B2 (ja) グリピカン3抗体およびそのコンジュゲート
JP2023515941A5 (cg-RX-API-DMAC7.html)
AU2016276751B2 (en) CD123 antibodies and conjugates thereof
CN105849126B (zh) 抗trop2抗体-药物偶联物
KR101529810B1 (ko) 항체-약물 접합체
JP2024544520A5 (cg-RX-API-DMAC7.html)
CN110770256B (zh) 靶向axl的抗体及抗体-药物偶联物及其制备方法和用途
EP4087613A1 (en) Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof
JP2022506072A5 (cg-RX-API-DMAC7.html)
JP2019536740A5 (cg-RX-API-DMAC7.html)
TWI726217B (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
JP7827624B2 (ja) 抗cea抗体-エキサテカン類似体複合体及びその医薬用途
JP2010535713A5 (cg-RX-API-DMAC7.html)
KR20140139480A (ko) 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법
KR102949500B1 (ko) 접합을 위한 폴리펩티드 복합체 및 이의 용도
JP7675818B2 (ja) 抗クローディン-18.2抗体及びその抗体薬物複合体
CN114828887A (zh) 抗-αVβ6抗体和抗体-药物偶联物
JP2021523100A5 (cg-RX-API-DMAC7.html)
JP2022523360A5 (cg-RX-API-DMAC7.html)
TW202245844A (zh) 抗dll3抗體-藥物結合物
WO2024076514A1 (en) C-c chemokine receptor type 8 (ccr8) antagonist antibodies
US20060051359A1 (en) Recombinant immunotoxin and use in treating tumors
EP4725968A1 (en) Anti-gpc3 antibody or antigen-binding fragment and use thereof
JP2026512687A (ja) ヒト化l1cam抗体-薬物複合体